The role of aspirin in cancer prevention
Top Cited Papers
- 3 April 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 9 (5), 259-267
- https://doi.org/10.1038/nrclinonc.2011.199
Abstract
Clinical guidelines for prophylactic aspirin use currently only consider the cardiovascular benefits of aspirin, weighed against the potential harm from aspirin-induced bleeding. Daily aspirin use has been convincingly shown to reduce the risk of colorectal cancer and recurrence of adenomatous polyps, but in average-risk populations, these benefits alone do not outweigh harms from aspirin-induced bleeding. Recently published secondary analyses of cardiovascular trials provide the first randomized evidence that daily aspirin use may also reduce the incidence of all cancers combined, even at low doses (75-100 mg daily). This Review considers the general mechanism of action that defines aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) as a class, the specific advantages of aspirin over other NSAIDs for prophylactic use, the current evidence concerning the main health outcomes affected by aspirin use, and the hypothesis that inhibition of platelet activation may mediate both the cardioprotective and cancer-preventive effects of low-dose aspirin. It also considers how even a 10% reduction in overall cancer incidence beginning during the first 10 years of treatment could tip the balance of benefits and risks favourably in average-risk populations.Keywords
This publication has 70 references indexed in Scilit:
- Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trialsThe Lancet, 2012
- Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trialsThe Lancet, 2012
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialThe Lancet, 2011
- Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trialsThe Lancet, 2010
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Aspirin Use and Survival After Diagnosis of Colorectal CancerJAMA, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studiesThe Lancet, 2007
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005